Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear ER α activation

The genito-urinary syndrome of menopause has a negative impact on quality of life of postmenopausal women. The treatment of vulvo-vaginal atrophy (VVA) includes administration of estrogens. However, oral estrogen treatment is controversial due to its potential risks on venous thrombosis and breast cancer. Estetrol (E4) is a natural estrogen synthesized exclusively during pregnancy by the human fetal liver and initially considered as a weak estrogen. However, E4 was recently evaluated in a phase I-II clinical studies and found to act as an oral contraceptive in combination with a progestin, without increasing the level of coagulation factors.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Regular Article Source Type: research